Citi analyst Geoff Meacham raised the firm’s price target on Biogen (BIIB) to $215 from $185 and keeps a Neutral rating on the shares. The firm views the company’s Q4 report as solid and remains optimistic on its ability to launch new products and develop its pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold
- Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating
- Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook
- Biogen price target raised to $196 from $165 at BMO Capital
- Midday Fly By: Amazon sinks on spending plans, Stellantis takes big charge